Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 777-786

  Fabunmi, Rosalind ^a   Nielsen, Loretta L ^a   Quimbo, Ralph ^b   Schroeder, Brock ^a   Misurski, Derek ^c   Wintle, Matthew ^a   Wade, Ron ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b HEALTHCORE INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide; Health outcomes; Hypoglycemia; Insulin glargine; Medical possession ratio; Obesity; Refill gap analysis; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY;

EID: 67649383239     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802715199     Document Type: Article

References (25)

1. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
2. Stonehouse AH, Maggs DG. Emerging therapies for type 2 diabetes. Curr Drug Ther 2007;2:151-160 (Pubitemid 46812952)
3. Nielsen LL, Okerson T, Holcombe J, et al. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diab Sci Tech 2008;2:255-260
4. Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33 (Pubitemid 351160873)
5. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin 2004;20:31-37 (Pubitemid 38063452)
6. Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE901) and NPH insulin. Diabetes Care 2001;24:631-636 (Pubitemid 32888839)
7. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955 (Pubitemid 40434505)
8. Heine RJ, Van Gaal LF, Johns D, et al. for the GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-569
9. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348 (Pubitemid 350298125)
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
11. Cameron AC, Trivedi PK. Regression Analysis of Count Data. New York: Cambridge University Press, 1998
12. Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-75 (Pubitemid 351312089)
13. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007;23:3017-3023
14. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87 (Pubitemid 350294021)
15. Segal JB, Griswold M, Ach-Brou A, et al. Using propensity scores subclassification to estimate effects of longitudinal treatments. Med Care 2007;45:S149-57
16. Ginde AA, Espinola JA, Camargo CA. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005. Diabetes Care 2008;31:511-513
17. Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health-Syst Pharm 2006;63:2473-2482 (Pubitemid 46391143)
18. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286 (Pubitemid 351160260)
19. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805-822 (Pubitemid 38029982)
20. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79
21. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-2589 (Pubitemid 38766335)
22. Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005;5:287-295 (Pubitemid 40667509)
23. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-172
24. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Eng J Med 2000;342:1887-1892 (Pubitemid 30419054)
25. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Eng J Med 2000;342:1878-1886 (Pubitemid 30419053)